Shares of Belgium-based TiGenix NV shot up more than 72 percent in pre-market trading after Japan’s Takeda Pharmaceuticals opted to acquire the company with which it has a developmental partnership for $630 million.
Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
The cancer death rate in 2015 was 14 percent higher in blacks than in whites, down from a peak of 33 percent in 1993.
The new total-body PET/CT scanner could revolutionize the understanding and treatment of disease through analysis of better imaging data from the whole body.
US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.
Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
The new card solution helps to simplify blood collection and sample transportation through providing a small amount of a patient’s blood from a fingertip.
An experimental drug being developed by Shire to treat cytomegalovirus (CMV) infection has been given a boost in the US with a ‘Breakthrough Therapy Designation’.
Indivior announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics (SIX: ADXN) ("Addex"), in the field of GABAB positive allosteric modulators (PAMs). GABAB PAMs have demonstrated preclinical efficacy and tolerability in animal models for alcohol use disorder (AUD) and cocaine use disorder (CUD)1,2.
Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.